ibrutinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 4810 936563-96-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • imbruvica
  • PCI-32765
  • CRA-032765
  • PCI-32765-00
  • ibrutinib
Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK's role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.
  • Molecular weight: 440.51
  • Formula: C25H24N6O2
  • CLOGP: 4.04
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 1
  • TPSA: 99.16
  • ALOGS: -4.34
  • ROTB: 5

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.42 g O

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 9.75 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.03 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 21, 2014 EMA
Nov. 13, 2013 FDA PHARMACYCLICS INC
March 28, 2016 PMDA Janssen Pharmaceutical

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 569.55 15.48 642 17763 324737 50261982
Atrial fibrillation 333.45 15.48 284 18121 101461 50485258
Incorrect dose administered 280.37 15.48 190 18215 48224 50538495
Off label use 170.89 15.48 465 17940 473961 50112758
Contusion 162.62 15.48 202 18203 111981 50474738
Petechiae 137.05 15.48 74 18331 12438 50574281
White blood cell count increased 124.13 15.48 111 18294 42129 50544590
Disease progression 116.03 15.48 158 18247 95708 50491011
Platelet count decreased 104.15 15.48 154 18251 100572 50486147
Tumour lysis syndrome 101.65 15.48 51 18354 7370 50579349
Lymphocytosis 98.04 15.48 35 18370 2167 50584552
Drug ineffective 97.85 15.48 93 18312 819240 49767479
Hospice care 95.08 15.48 45 18360 5727 50580992
Lymphadenopathy 94.40 15.48 86 18319 33413 50553306
Pleural effusion 80.54 15.48 122 18283 81332 50505387
Subdural haematoma 77.66 15.48 52 18353 12895 50573824
Drug hypersensitivity 74.99 15.48 4 18401 251006 50335713
Haemorrhage 70.61 15.48 92 18313 53349 50533370
Epistaxis 69.26 15.48 100 18305 63854 50522865
Haematoma 68.28 15.48 69 18336 30441 50556278
Thrombocytopenia 66.81 15.48 145 18260 127528 50459191
Haemorrhage intracranial 65.47 15.48 46 18359 12328 50574391
Lymphocyte count increased 64.34 15.48 28 18377 2931 50583788
Ecchymosis 61.37 15.48 41 18364 10128 50576591
Onychoclasis 60.45 15.48 32 18373 5164 50581555
Progressive multifocal leukoencephalopathy 59.25 15.48 42 18363 11415 50575304
Product use in unapproved indication 56.59 15.48 128 18277 115691 50471028
Aspergillus infection 54.91 15.48 33 18372 6788 50579931
Pneumonia 52.81 15.48 274 18131 378127 50208592
Rheumatoid arthritis 52.75 15.48 6 18399 202544 50384175
Cerebral haemorrhage 51.28 15.48 56 18349 26996 50559723
Pericardial effusion 48.56 15.48 53 18352 25536 50561183
Pain 47.07 15.48 87 18318 578816 50007903
Neutropenia 45.96 15.48 138 18267 147827 50438892
Increased tendency to bruise 45.40 15.48 33 18372 9323 50577396
Hospitalisation 44.83 15.48 85 18320 67852 50518867
Capillary permeability increased 43.79 15.48 8 18397 26 50586693
Haemoglobin decreased 42.71 15.48 122 18283 127094 50459625
Contraindicated product administered 42.57 15.48 3 18402 148955 50437764
Autoimmune haemolytic anaemia 41.97 15.48 23 18382 3976 50582743
Infusion related reaction 41.77 15.48 6 18399 169551 50417168
Arthropathy 40.30 15.48 5 18400 157901 50428818
Sepsis 39.42 15.48 122 18283 132803 50453916
Condition aggravated 38.50 15.48 31 18374 297027 50289692
Leukocytosis 38.11 15.48 44 18361 22535 50564184
Muscle spasms 37.94 15.48 116 18289 125437 50461282
Haematotympanum 37.36 15.48 6 18399 6 50586713
Blood blister 37.05 15.48 16 18389 1644 50585075
Completed suicide 36.71 15.48 3 18402 131886 50454833
Urinary tract infection 35.99 15.48 169 18236 223851 50362868
Neutrophil count decreased 35.98 15.48 62 18343 45964 50540755
Non-small cell lung cancer 33.92 15.48 18 18387 2919 50583800
Eye haemorrhage 33.62 15.48 25 18380 7310 50579409
Hyperuricaemia 33.48 15.48 21 18384 4659 50582060
Febrile neutropenia 33.09 15.48 94 18311 97573 50489146
Cytopenia 31.74 15.48 26 18379 8749 50577970
Therapeutic product effect decreased 30.87 15.48 6 18399 136044 50450675
Diarrhoea 29.98 15.48 336 18069 588140 49998579
Toxicity to various agents 29.01 15.48 21 18384 212478 50374241
Chronic lymphocytic leukaemia refractory 28.81 15.48 6 18399 44 50586675
COVID-19 27.87 15.48 56 18349 46606 50540113
Haematuria 27.63 15.48 40 18365 25573 50561146
Splenomegaly 27.58 15.48 25 18380 9635 50577084
Bronchopulmonary aspergillosis 26.43 15.48 22 18383 7570 50579149
Swelling 25.95 15.48 21 18384 200851 50385868
Purpura 25.12 15.48 24 18381 9887 50576832
Splenic haematoma 24.38 15.48 6 18399 99 50586620
Hepatic enzyme increased 23.92 15.48 10 18395 137370 50449349
Full blood count abnormal 23.04 15.48 35 18370 23353 50563366
Hypogammaglobulinaemia 22.99 15.48 18 18387 5681 50581038
Hypersensitivity 22.59 15.48 27 18378 215134 50371585
Haemothorax 22.56 15.48 12 18393 1954 50584765
Meningitis cryptococcal 22.21 15.48 10 18395 1135 50585584
Fall 22.16 15.48 202 18203 334730 50251989
Discomfort 22.15 15.48 6 18399 108374 50478345
Lymphoma 22.00 15.48 22 18383 9579 50577140
Discouragement 21.66 15.48 8 18397 546 50586173
Ear haemorrhage 21.47 15.48 10 18395 1227 50585492
Wound 21.36 15.48 6 18399 105788 50480931
Abdominal discomfort 21.35 15.48 32 18373 231609 50355110
Chronic lymphocytic leukaemia recurrent 20.89 15.48 6 18399 183 50586536
Cerebral aspergillosis 20.85 15.48 7 18398 360 50586359
Nonspecific reaction 20.82 15.48 11 18394 1768 50584951
Chronic lymphocytic leukaemia 20.64 15.48 12 18393 2321 50584398
Hyperphosphataemia 20.30 15.48 11 18394 1860 50584859
Cardiac failure 19.98 15.48 67 18338 75973 50510746
Musculoskeletal stiffness 19.85 15.48 11 18394 128470 50458249
Skin lesion 19.58 15.48 35 18370 26692 50560027
Gingival bleeding 18.94 15.48 22 18383 11331 50575388
Diffuse large B-cell lymphoma 18.87 15.48 16 18389 5646 50581073
Product use issue 18.55 15.48 105 18300 149370 50437349
Pneumonia fungal 18.20 15.48 14 18391 4306 50582413
Atrial flutter 18.12 15.48 19 18386 8744 50577975
Joint swelling 18.01 15.48 39 18366 245247 50341472
Skin haemorrhage 18.00 15.48 17 18388 6901 50579818
Spinal fracture 17.79 15.48 25 18380 15548 50571171
Sudden death 17.71 15.48 19 18386 8972 50577747
Drug intolerance 17.65 15.48 33 18372 219071 50367648
Leukostasis syndrome 17.51 15.48 4 18401 47 50586672
Septic shock 17.41 15.48 53 18352 57122 50529597
White blood cell count abnormal 17.37 15.48 15 18390 5425 50581294
Hyperviscosity syndrome 17.09 15.48 5 18400 163 50586556
Haemorrhagic diathesis 17.08 15.48 13 18392 3935 50582784
Pyrexia 17.02 15.48 212 18193 379991 50206728
Campylobacter gastroenteritis 16.87 15.48 6 18399 367 50586352
Cytomegalovirus infection reactivation 16.82 15.48 11 18394 2620 50584099
Anaemia 16.54 15.48 152 18253 252304 50334415
Nail disorder 16.51 15.48 19 18386 9689 50577030
Hypercalcaemia 16.36 15.48 30 18375 23322 50563397
Breast haematoma 16.23 15.48 5 18400 195 50586524
Overdose 16.20 15.48 8 18397 99719 50487000
Lichenification 16.12 15.48 6 18399 418 50586301
Chronic graft versus host disease 15.96 15.48 11 18394 2856 50583863
Pseudohyperkalaemia 15.94 15.48 3 18402 12 50586707
Mantle cell lymphoma 15.83 15.48 6 18399 440 50586279
Psoriasis 15.74 15.48 3 18402 68997 50517722
Splenic rupture 15.72 15.48 8 18397 1190 50585529

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Atrial fibrillation 674.08 13.30 729 34998 104917 29433883
Death 594.57 13.30 1283 34444 340801 29197999
Incorrect dose administered 393.89 13.30 323 35404 32661 29506139
Lymphocytosis 229.88 13.30 87 35640 1853 29536947
Off label use 228.79 13.30 838 34889 299962 29238838
Disease progression 219.28 13.30 371 35356 81545 29457255
Contusion 210.46 13.30 222 35505 30873 29507927
Lymphocyte count increased 208.98 13.30 90 35637 2704 29536096
Haemorrhage 181.47 13.30 247 35480 44825 29493975
Lymphadenopathy 143.68 13.30 164 35563 24885 29513915
White blood cell count increased 138.12 13.30 197 35530 37319 29501481
Pleural effusion 132.76 13.30 278 35449 71630 29467170
Toxicity to various agents 127.90 13.30 27 35700 173634 29365166
Bronchopulmonary aspergillosis 118.89 13.30 107 35620 12237 29526563
Platelet count decreased 118.45 13.30 335 35392 104337 29434463
Subdural haematoma 116.16 13.30 126 35601 18067 29520733
Cerebral aspergillosis 115.80 13.30 48 35679 1308 29537492
Pneumonia 107.68 13.30 707 35020 319465 29219335
Tumour lysis syndrome 104.48 13.30 105 35622 13779 29525021
Petechiae 96.05 13.30 81 35646 8490 29530310
Completed suicide 91.95 13.30 4 35723 90242 29448558
Product use issue 89.23 13.30 194 35533 51250 29487550
Haematoma 87.03 13.30 123 35604 23089 29515711
Mantle cell lymphoma recurrent 84.00 13.30 29 35698 469 29538331
Pericardial effusion 81.91 13.30 114 35613 21094 29517706
Increased tendency to bruise 76.97 13.30 50 35677 3512 29535288
Basal cell carcinoma 73.06 13.30 96 35631 16814 29521986
Scleroderma 71.20 13.30 34 35693 1304 29537496
Haemothorax 68.82 13.30 46 35681 3390 29535410
Hypogammaglobulinaemia 68.61 13.30 57 35670 5850 29532950
Autoimmune haemolytic anaemia 66.41 13.30 47 35680 3801 29534999
Splenomegaly 64.65 13.30 80 35647 13199 29525601
Hospice care 63.27 13.30 51 35676 5017 29533783
Atrial flutter 60.21 13.30 79 35648 13815 29524985
COVID-19 58.12 13.30 132 35595 35882 29502918
Drug ineffective 56.98 13.30 236 35491 362934 29175866
Epistaxis 56.92 13.30 164 35563 51540 29487260
Overdose 55.50 13.30 14 35713 79805 29458995
Aspergillus infection 55.17 13.30 66 35661 10515 29528285
Cerebral haemorrhage 52.74 13.30 117 35610 31309 29507491
Microsporidia infection 51.72 13.30 21 35706 542 29538258
Haemoglobin decreased 48.85 13.30 259 35468 108116 29430684
Haematuria 48.57 13.30 140 35587 43999 29494801
White blood cell count abnormal 45.20 13.30 33 35694 2802 29535998
Chronic lymphocytic leukaemia recurrent 44.95 13.30 17 35710 361 29538439
Post procedural haemorrhage 44.54 13.30 50 35677 7441 29531359
Product use in unapproved indication 42.17 13.30 212 35515 86663 29452137
Hospitalisation 41.40 13.30 136 35591 45852 29492948
Cardiac failure 40.27 13.30 196 35531 79091 29459709
Mantle cell lymphoma refractory 39.66 13.30 11 35716 81 29538719
Surgery 39.17 13.30 59 35668 11720 29527080
Subdural haemorrhage 38.54 13.30 30 35697 2805 29535995
Neutrophil count decreased 38.47 13.30 128 35599 43439 29495361
Chronic lymphocytic leukaemia 37.98 13.30 33 35694 3600 29535200
Agitation 37.64 13.30 8 35719 51296 29487504
Condition aggravated 37.59 13.30 75 35652 146220 29392580
Mantle cell lymphoma 37.51 13.30 21 35706 1124 29537676
Ecchymosis 37.48 13.30 42 35685 6238 29532562
Platelet count abnormal 36.22 13.30 27 35700 2367 29536433
Drug hypersensitivity 35.76 13.30 19 35708 68387 29470413
Prostatic operation 35.74 13.30 14 35713 328 29538472
Vomiting 35.67 13.30 134 35593 212126 29326674
Splenic rupture 35.48 13.30 22 35705 1424 29537376
Blood immunoglobulin M increased 35.29 13.30 12 35715 185 29538615
Blood blister 35.07 13.30 22 35705 1454 29537346
Somnolence 34 13.30 38 35689 93917 29444883
Nausea 33.81 13.30 208 35519 289047 29249753
Plasma cell myeloma 33.75 13.30 3 35724 37112 29501688
Intentional overdose 32.75 13.30 4 35723 38524 29500276
Lymphocyte count decreased 32.61 13.30 72 35655 19199 29519601
Haemorrhage subcutaneous 32.22 13.30 24 35703 2101 29536699
Pericarditis 32.21 13.30 46 35681 8711 29530089
Haemorrhagic diathesis 31.94 13.30 26 35701 2592 29536208
Brain abscess 31.62 13.30 26 35701 2629 29536171
Chronic graft versus host disease 31.27 13.30 31 35696 3998 29534802
Blood urine present 31.22 13.30 48 35679 9707 29529093
Squamous cell carcinoma 30.80 13.30 49 35678 10202 29528598
Blood pressure decreased 29.69 13.30 9 35718 45468 29493332
Angina bullosa haemorrhagica 29.57 13.30 8 35719 53 29538747
Polymyositis 29.57 13.30 19 35708 1309 29537491
Metabolic acidosis 29.48 13.30 5 35722 37657 29501143
Blood pressure increased 28.78 13.30 28 35699 73775 29465025
Anxiety 28.26 13.30 37 35690 85328 29453472
Skin haemorrhage 28.26 13.30 28 35699 3609 29535191
Infective exacerbation of chronic obstructive airways disease 28.12 13.30 20 35707 1630 29537170
Chronic lymphocytic leukaemia transformation 27.97 13.30 10 35717 180 29538620
Haemorrhage intracranial 27.68 13.30 57 35670 14485 29524315
Pseudomonas infection 27.42 13.30 48 35679 10804 29527996
Pericardial haemorrhage 27.41 13.30 25 35702 2906 29535894
Stomatitis 26.73 13.30 102 35625 37011 29501789
Chronic graft versus host disease in skin 26.71 13.30 15 35712 808 29537992
Bacterial pericarditis 26.61 13.30 7 35720 41 29538759
Ear haemorrhage 26.54 13.30 15 35712 818 29537982
Hypoglycaemia 25.90 13.30 13 35714 48333 29490467
Electrocardiogram QT prolonged 25.77 13.30 6 35721 36131 29502669
Suicide attempt 25.68 13.30 5 35722 34105 29504695
COVID-19 pneumonia 25.22 13.30 43 35684 9479 29529321
Iodine uptake abnormal 25.14 13.30 5 35722 5 29538795
Lymphoma transformation 25.13 13.30 9 35718 163 29538637
Rhabdomyolysis 24.97 13.30 22 35705 60786 29478014
Bone marrow transplant 24.85 13.30 15 35712 925 29537875
Suicidal ideation 24.29 13.30 6 35721 34710 29504090
Intentional product misuse 24.23 13.30 6 35721 34655 29504145
Mass 24.19 13.30 36 35691 7075 29531725
Pulmonary mass 23.93 13.30 45 35682 10703 29528097
Leukostasis syndrome 23.61 13.30 6 35721 30 29538770
Renal impairment 23.27 13.30 39 35688 81294 29457506
Tremor 23.20 13.30 33 35694 73505 29465295
Haemolytic anaemia 22.95 13.30 41 35686 9378 29529422
Depressed level of consciousness 22.90 13.30 8 35719 36934 29501866
Onychoclasis 22.64 13.30 18 35709 1735 29537065
Immunodeficiency common variable 22.64 13.30 8 35719 139 29538661
Loss of consciousness 22.61 13.30 34 35693 74022 29464778
Hallucination 22.52 13.30 13 35714 44699 29494101
Arrhythmia 22.49 13.30 86 35641 31227 29507573
International normalised ratio increased 22.21 13.30 13 35714 44359 29494441
Immunodeficiency 22.01 13.30 27 35700 4413 29534387
Thrombocytopenia 21.86 13.30 254 35473 134569 29404231
Febrile neutropenia 21.69 13.30 219 35508 112021 29426779
Granuloma skin 21.54 13.30 12 35715 636 29538164
Pyrexia 21.21 13.30 475 35252 287147 29251653
Cardiac tamponade 21.08 13.30 27 35700 4608 29534192
Splenic haemorrhage 20.86 13.30 10 35717 387 29538413
Abdominal lymphadenopathy 20.68 13.30 12 35715 688 29538112
Eye haemorrhage 20.62 13.30 24 35703 3712 29535088
Pyoderma gangrenosum 20.43 13.30 14 35713 1075 29537725
Haemorrhagic disorder 20.30 13.30 11 35716 552 29538248
Bladder operation 20.29 13.30 7 35720 113 29538687
Conjunctival haemorrhage 19.86 13.30 20 35707 2628 29536172
Eye operation 19.83 13.30 9 35718 307 29538493
Neutropenia 19.54 13.30 244 35483 131467 29407333
Pneumonia cryptococcal 19.53 13.30 12 35715 764 29538036
Leukocytosis 19.44 13.30 63 35664 21079 29517721
Meningitis enteroviral 19.35 13.30 5 35722 27 29538773
Pulmonary embolism 18.98 13.30 40 35687 76494 29462306
Muscle spasms 18.88 13.30 139 35588 64943 29473857
Anaphylactic reaction 18.84 13.30 5 35722 27568 29511232
Hyperphosphataemia 18.83 13.30 18 35709 2220 29536580
Mucormycosis 18.83 13.30 27 35700 5131 29533669
Urticaria 18.80 13.30 23 35704 54637 29484163
Sepsis 18.53 13.30 258 35469 142424 29396376
Flushing 18.45 13.30 6 35721 28986 29509814
Gastric haemorrhage 18.35 13.30 37 35690 9260 29529540
Cardiomyopathy 18.32 13.30 49 35678 14738 29524062
Biopsy 18.07 13.30 7 35720 159 29538641
Pneumonia fungal 17.89 13.30 28 35699 5749 29533051
Wheezing 17.71 13.30 9 35718 33231 29505569
Blood urea increased 17.57 13.30 6 35721 28106 29510694
Ureteric compression 17.48 13.30 7 35720 174 29538626
Musculoskeletal stiffness 17.34 13.30 12 35715 37446 29501354
Lymphoedema 17.29 13.30 21 35706 3396 29535404
Subarachnoid haemorrhage 17.29 13.30 37 35690 9655 29529145
Herpes zoster 17.22 13.30 77 35650 29975 29508825
Therapeutic product effect decreased 17.21 13.30 7 35720 29444 29509356
Hepatitis E 17.08 13.30 15 35712 1659 29537141
Skin cancer 17.07 13.30 34 35693 8434 29530366
Chronic graft versus host disease in eye 17.04 13.30 5 35722 46 29538754
Cryptococcosis 17.00 13.30 16 35711 1936 29536864
Aggression 16.97 13.30 11 35716 35530 29503270
Malaise 16.95 13.30 118 35609 159484 29379316
Pruritus 16.95 13.30 78 35649 116771 29422029
Myositis 16.92 13.30 38 35689 10245 29528555
Full blood count abnormal 16.87 13.30 48 35679 14965 29523835
Psoriasis 16.76 13.30 9 35718 32218 29506582
Peripheral swelling 16.74 13.30 133 35594 63606 29475194
Respiratory failure 16.63 13.30 185 35542 96946 29441854
Gamma-glutamyltransferase increased 16.21 13.30 6 35721 26731 29512069
Thyroxine increased 16.16 13.30 5 35722 56 29538744
Hypotension 15.93 13.30 154 35573 194200 29344600
Skin lesion 15.88 13.30 54 35673 18518 29520282
Transplant 15.59 13.30 10 35717 687 29538113
Cerebral fungal infection 15.58 13.30 7 35720 233 29538567
Skin mass 15.57 13.30 20 35707 3423 29535377
Hypersensitivity 15.47 13.30 25 35702 52878 29485922
Abdominal pain 15.41 13.30 98 35629 135259 29403541
Blood glucose increased 15.33 13.30 30 35697 58954 29479846
Pain 15.28 13.30 133 35594 171299 29367501
Papilloma excision 15.08 13.30 3 35724 3 29538797
Mastoid effusion 15.08 13.30 3 35724 3 29538797
Lymph node haemorrhage 15.08 13.30 3 35724 3 29538797
Application site laceration 15.08 13.30 3 35724 3 29538797
Deep vein thrombosis 15.08 13.30 29 35698 57370 29481430
Product use complaint 15.07 13.30 11 35716 933 29537867
Scrotal haematocoele 14.99 13.30 4 35723 25 29538775
Acute kidney injury 14.96 13.30 228 35499 265039 29273761
Bradycardia 14.89 13.30 36 35691 65593 29473207
Altered state of consciousness 14.79 13.30 3 35724 19886 29518914
Vitreous haemorrhage 14.73 13.30 15 35712 1998 29536802
Tachyarrhythmia 14.63 13.30 18 35709 2951 29535849
Hypercalcaemia 14.53 13.30 41 35686 12718 29526082
Soft tissue infection 14.45 13.30 14 35713 1755 29537045
Heart rate decreased 14.43 13.30 6 35721 24906 29513894
Human rhinovirus test positive 14.35 13.30 6 35721 167 29538633
Abnormal behaviour 14.34 13.30 5 35722 23122 29515678
Confusional state 14.34 13.30 93 35634 127784 29411016
Seizure 14.20 13.30 61 35666 93062 29445738
Night sweats 14.19 13.30 45 35682 14887 29523913
Sudden death 13.84 13.30 43 35684 14067 29524733
C-reactive protein increased 13.82 13.30 20 35707 44243 29494557
Angioedema 13.77 13.30 11 35716 31904 29506896
Peptic ulcer haemorrhage 13.76 13.30 8 35719 460 29538340
Beta 2 microglobulin increased 13.75 13.30 6 35721 186 29538614
Fungal abscess central nervous system 13.64 13.30 5 35722 97 29538703
Transurethral prostatectomy 13.52 13.30 7 35720 320 29538480
Paraesthesia 13.47 13.30 28 35699 53817 29484983
Gout 13.44 13.30 48 35679 16863 29521937
Hyperhidrosis 13.41 13.30 37 35690 64503 29474297
Enterovirus infection 13.40 13.30 9 35718 668 29538132
Eosinophilia 13.39 13.30 5 35722 22156 29516644
Loss of personal independence in daily activities 13.38 13.30 7 35720 25433 29513367
Irritability 13.38 13.30 5 35722 22147 29516653
Restlessness 13.37 13.30 5 35722 22140 29516660
Aspartate aminotransferase increased 13.36 13.30 33 35694 59692 29479108

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Atrial fibrillation 965.43 13.47 866 44754 170223 64282889
Incorrect dose administered 618.86 13.47 436 45184 60329 64392783
Death 404.66 13.47 985 44635 481720 63971392
Off label use 310.04 13.47 1065 44555 631741 63821371
Lymphocytosis 283.24 13.47 104 45516 3540 64449572
Platelet count decreased 242.17 13.47 429 45191 167282 64285830
White blood cell count increased 238.82 13.47 263 45357 65751 64387361
Lymphocyte count increased 231.65 13.47 98 45522 4877 64448235
Contusion 222.11 13.47 334 45286 113631 64339481
Disease progression 210.39 13.47 367 45253 141313 64311799
Pleural effusion 207.98 13.47 343 45277 126216 64326896
Petechiae 199.51 13.47 138 45482 18488 64434624
Lymphadenopathy 197.18 13.47 202 45418 46484 64406628
Subdural haematoma 194.03 13.47 160 45460 27894 64425218
Pneumonia 187.06 13.47 836 44784 558740 63894372
Tumour lysis syndrome 182.73 13.47 133 45487 19307 64433805
Bronchopulmonary aspergillosis 171.32 13.47 127 45493 18958 64434154
Toxicity to various agents 156.92 13.47 33 45587 363480 64089632
Cerebral aspergillosis 149.10 13.47 53 45567 1640 64451472
Haematoma 141.44 13.47 169 45451 46081 64407031
Completed suicide 140.27 13.47 4 45616 224410 64228702
Pericardial effusion 136.06 13.47 153 45467 39101 64414011
Drug ineffective 134.45 13.47 244 45376 840003 63613109
Haemorrhage 126.14 13.47 212 45408 79139 64373973
Aspergillus infection 108.22 13.47 91 45529 16288 64436824
Drug hypersensitivity 108.02 13.47 19 45601 237796 64215316
Epistaxis 105.78 13.47 222 45398 97909 64355203
Increased tendency to bruise 100.10 13.47 69 45551 9186 64443926
Haemoglobin decreased 97.04 13.47 331 45289 194732 64258380
Rheumatoid arthritis 95.61 13.47 5 45615 164289 64288823
Haematuria 95.34 13.47 161 45459 60310 64392802
Thrombocytopenia 92.07 13.47 357 45263 223444 64229668
Atrial flutter 91.26 13.47 89 45531 19291 64433821
Cerebral haemorrhage 88.59 13.47 142 45478 50948 64402164
Mantle cell lymphoma recurrent 82.32 13.47 25 45595 465 64452647
Product use in unapproved indication 82.01 13.47 293 45327 176325 64276787
Autoimmune haemolytic anaemia 81.86 13.47 55 45565 7021 64446091
Condition aggravated 81.50 13.47 86 45534 372340 64080772
Ecchymosis 80.69 13.47 72 45548 13950 64439162
Neutrophil count decreased 78.97 13.47 171 45449 77025 64376087
Cardiac failure 77.90 13.47 238 45382 132135 64320977
Haemothorax 76.94 13.47 46 45574 4796 64448316
Hypogammaglobulinaemia 75.95 13.47 61 45559 10238 64442874
Splenomegaly 74.50 13.47 77 45543 17884 64435228
Haemorrhage intracranial 74.19 13.47 88 45532 23796 64429316
Pain 70.58 13.47 182 45438 553329 63899783
Overdose 69.75 13.47 14 45606 159552 64293560
Sepsis 69.74 13.47 335 45285 230006 64223106
COVID-19 68.58 13.47 146 45474 64994 64388118
Basal cell carcinoma 66.66 13.47 95 45525 30743 64422369
Nausea 63.73 13.47 313 45307 785487 63667625
Blood blister 61.17 13.47 32 45588 2576 64450536
Febrile neutropenia 60.49 13.47 278 45342 187379 64265733
Neutropenia 59.66 13.47 330 45290 239294 64213818
Chronic lymphocytic leukaemia 58.38 13.47 37 45583 4278 64448834
Mantle cell lymphoma 58.09 13.47 24 45596 1124 64451988
Leukocytosis 57.51 13.47 99 45521 37641 64415471
Product use issue 55.92 13.47 234 45386 151481 64301631
Microsporidia infection 55.85 13.47 21 45599 764 64452348
Therapeutic product effect decreased 55.07 13.47 8 45612 115343 64337769
Contraindicated product administered 55.07 13.47 6 45614 107823 64345289
Chronic lymphocytic leukaemia recurrent 54.74 13.47 19 45601 547 64452565
White blood cell count abnormal 54.41 13.47 37 45583 4817 64448295
Onychoclasis 53.86 13.47 36 45584 4556 64448556
Arthropathy 52.06 13.47 11 45609 120956 64332156
Pyrexia 50.97 13.47 611 45009 558033 63895079
Post procedural haemorrhage 49.24 13.47 52 45568 12379 64440733
Mantle cell lymphoma refractory 48.65 13.47 12 45608 97 64453015
Brain abscess 47.17 13.47 32 45588 4149 64448963
Intentional overdose 45.94 13.47 5 45615 89939 64363173
Infusion related reaction 45.75 13.47 30 45590 164437 64288675
Drug intolerance 45.01 13.47 40 45580 187952 64265160
Muscle spasms 44.00 13.47 207 45413 140816 64312296
Hypersensitivity 43.31 13.47 45 45575 196407 64256705
Capillary permeability increased 43.12 13.47 9 45611 30 64453082
Platelet count abnormal 42.92 13.47 30 45590 4082 64449030
Hyperuricaemia 42.82 13.47 44 45576 10147 64442965
Subdural haemorrhage 42.52 13.47 33 45587 5270 64447842
Squamous cell carcinoma 41.26 13.47 50 45570 13819 64439293
Leukostasis syndrome 41.09 13.47 10 45610 76 64453036
Musculoskeletal stiffness 40.81 13.47 18 45602 123188 64329924
Ear haemorrhage 40.70 13.47 22 45598 1892 64451220
Splenic rupture 40.32 13.47 23 45597 2196 64450916
Hepatic enzyme increased 39.96 13.47 21 45599 129922 64323190
Chronic lymphocytic leukaemia transformation 39.62 13.47 12 45608 221 64452891
Haematotympanum 39.48 13.47 8 45612 22 64453090
Hyperphosphataemia 39.14 13.47 28 45592 3953 64449159
Eye haemorrhage 38.62 13.47 38 45582 8322 64444790
Arrhythmia 37.70 13.47 102 45518 52842 64400270
Progressive multifocal leukoencephalopathy 37.69 13.47 55 45565 18177 64434935
Malaise 37.32 13.47 149 45471 396098 64057014
Agitation 36.09 13.47 9 45611 88358 64364754
Prostatic operation 36.05 13.47 11 45609 208 64452904
COVID-19 pneumonia 35.89 13.47 51 45569 16453 64436659
Urticaria 35.68 13.47 31 45589 147286 64305826
Purpura 35.61 13.47 52 45568 17194 64435918
Haemorrhagic diathesis 35.11 13.47 30 45590 5484 64447628
Pseudomonas infection 34.18 13.47 52 45568 17831 64435281
Skin haemorrhage 34.16 13.47 36 45584 8549 64444563
Flushing 34.14 13.47 7 45613 78641 64374471
Abdominal discomfort 33.59 13.47 48 45572 182274 64270838
Diarrhoea 33.24 13.47 705 44915 721999 63731113
Infective exacerbation of chronic obstructive airways disease 33.22 13.47 21 45599 2417 64450695
Blood urine present 33.19 13.47 52 45568 18288 64434824
Respiratory failure 33.00 13.47 211 45409 160972 64292140
Mobility decreased 32.71 13.47 10 45610 85830 64367282
Anxiety 32.04 13.47 59 45561 202590 64250522
Discomfort 31.59 13.47 9 45611 80869 64372243
Suicide attempt 31.50 13.47 6 45614 71001 64382111
Pneumonia fungal 31.42 13.47 35 45585 8842 64444270
Gastric haemorrhage 31.32 13.47 43 45577 13438 64439674
Alopecia 31.14 13.47 43 45577 165647 64287465
Cytopenia 31.01 13.47 46 45574 15425 64437687
Swelling 30.70 13.47 41 45579 160177 64292935
Haemorrhage subcutaneous 30.40 13.47 25 45595 4336 64448776
Scleroderma 30.25 13.47 26 45594 4792 64448320
Intentional product misuse 30.24 13.47 7 45613 72288 64380824
Haemolytic anaemia 29.72 13.47 46 45574 16007 64437105
Glossodynia 29.71 13.47 5 45615 64691 64388421
Bacterial pericarditis 29.65 13.47 7 45613 46 64453066
Joint swelling 29.57 13.47 68 45552 215314 64237798
Lymphocyte count decreased 29.57 13.47 79 45541 40620 64412492
Pericardial haemorrhage 29.44 13.47 24 45596 4112 64449000
Electrocardiogram QT prolonged 28.96 13.47 10 45610 79438 64373674
Subarachnoid haemorrhage 28.92 13.47 49 45571 18389 64434723
Vomiting 28.53 13.47 251 45369 550866 63902246
Cryptococcosis 28.52 13.47 20 45600 2735 64450377
Hypoglycaemia 28.42 13.47 14 45606 89878 64363234
Depressed level of consciousness 28.41 13.47 11 45609 81425 64371687
Blood pressure increased 28.39 13.47 49 45571 172503 64280609
Sudden death 28.39 13.47 51 45569 20045 64433067
Blood creatine phosphokinase increased 28.08 13.47 4 45616 58554 64394558
Anaphylactic reaction 28.03 13.47 7 45613 68657 64384455
Iodine uptake abnormal 27.81 13.47 5 45615 5 64453107
Full blood count abnormal 27.14 13.47 63 45557 29694 64423418
Chronic graft versus host disease in skin 26.85 13.47 15 45605 1376 64451736
Haemoptysis 26.80 13.47 86 45534 48962 64404150
Suicidal ideation 26.74 13.47 7 45613 66535 64386577
Gingival bleeding 26.72 13.47 42 45578 14812 64438300
Loss of personal independence in daily activities 26.61 13.47 9 45611 72445 64380667
Polymyositis 26.50 13.47 19 45601 2691 64450421
Blood pressure decreased 26.40 13.47 14 45606 86185 64366927
Lymphoma 25.88 13.47 40 45580 13901 64439211
Skin lesion 25.68 13.47 70 45550 36412 64416700
Asthma 25.63 13.47 18 45602 95207 64357905
Wound 25.59 13.47 11 45609 76466 64376646
Oxygen saturation decreased 25.41 13.47 23 45597 107153 64345959
Cardiac tamponade 25.21 13.47 30 45590 8134 64444978
Psoriasis 24.50 13.47 10 45610 71693 64381419
Chronic graft versus host disease 24.40 13.47 26 45594 6250 64446862
Laboratory test abnormal 24.24 13.47 53 45567 24010 64429102
Abdominal lymphadenopathy 24.10 13.47 13 45607 1113 64451999
Fungal abscess central nervous system 23.86 13.47 7 45613 115 64452997
Pneumonitis 23.71 13.47 84 45536 50281 64402831
Gout 23.69 13.47 49 45571 21364 64431748
Somnolence 23.59 13.47 70 45550 203575 64249537
Biopsy 23.51 13.47 10 45610 504 64452608
Lymphoma transformation 23.50 13.47 8 45612 217 64452895
Wheezing 23.36 13.47 14 45606 80565 64372547
Skin cancer 23.14 13.47 35 45585 11939 64441173
International normalised ratio increased 22.61 13.47 14 45606 79153 64373959
Metabolic acidosis 22.51 13.47 11 45609 70947 64382165
Hospitalisation 22.43 13.47 109 45511 75098 64378014
Cytokine release syndrome 22.27 13.47 47 45573 20782 64432330
White blood cell count decreased 22.21 13.47 189 45431 157648 64295464
Immunodeficiency common variable 22.04 13.47 8 45612 263 64452849
Pyoderma gangrenosum 22.00 13.47 18 45602 3100 64450012
Pruritus 21.57 13.47 131 45489 312269 64140843
Inguinal hernia 21.49 13.47 23 45597 5558 64447554
Paraesthesia 21.40 13.47 39 45581 134483 64318629
Infectious pleural effusion 21.20 13.47 17 45603 2845 64450267
Mucormycosis 21.08 13.47 26 45594 7315 64445797
Ureteric compression 21.06 13.47 7 45613 176 64452936
Tremor 20.99 13.47 46 45574 148184 64304928
Cytomegalovirus infection reactivation 20.90 13.47 23 45597 5733 64447379
Blood cholesterol increased 20.63 13.47 5 45615 50061 64403051
Beta 2 microglobulin increased 20.49 13.47 8 45612 323 64452789
Meningitis cryptococcal 20.46 13.47 17 45603 2992 64450120
Weight increased 20.19 13.47 80 45540 213268 64239844
Vitreous haemorrhage 20.09 13.47 17 45603 3068 64450044
Gait disturbance 20.06 13.47 59 45561 172096 64281016
Conjunctival haemorrhage 19.88 13.47 21 45599 5000 64448112
Anaemia 19.85 13.47 377 45243 378303 64074809
Discouragement 19.78 13.47 10 45610 749 64452363
Haemolysis 19.56 13.47 31 45589 11008 64442104
Pneumocystis jirovecii pneumonia 19.43 13.47 53 45567 27581 64425531
Coma 19.37 13.47 20 45600 87595 64365517
Chronic lymphocytic leukaemia refractory 19.35 13.47 6 45614 120 64452992
Blood uric acid increased 18.90 13.47 26 45594 8137 64444975
Pulmonary mass 18.86 13.47 48 45572 23968 64429144
Urinary tract infection 18.74 13.47 248 45372 231348 64221764
Non-small cell lung cancer 18.56 13.47 20 45600 4870 64448242
Abdominal pain 18.55 13.47 137 45483 312238 64140874
Prostatectomy 18.40 13.47 6 45614 142 64452970
Plasma cell myeloma 18.23 13.47 5 45615 46070 64407042
Cardiomyopathy 18.20 13.47 49 45571 25307 64427805
Hallucination 18 13.47 15 45605 72773 64380339
Hypercalcaemia 18.00 13.47 56 45564 31360 64421752
Haemophagocytic lymphohistiocytosis 17.98 13.47 39 45581 17570 64435542
Meningitis enteroviral 17.92 13.47 5 45615 68 64453044
Surgery 17.77 13.47 52 45568 28161 64424951
Pneumonia cryptococcal 17.71 13.47 11 45609 1228 64451884
SARS-CoV-2 test positive 17.63 13.47 22 45598 6264 64446848
Helicobacter infection 17.53 13.47 3 45617 38359 64414753
Product use complaint 17.16 13.47 12 45608 1634 64451478
Hepatitis E 17.08 13.47 14 45606 2417 64450695
Therapy non-responder 17.02 13.47 13 45607 65886 64387226
Transurethral prostatectomy 16.93 13.47 6 45614 184 64452928
Stress 16.88 13.47 11 45609 60523 64392589
Toxic epidermal necrolysis 16.78 13.47 3 45617 37163 64415949
Renal impairment 16.67 13.47 45 45575 134972 64318140
Wrong technique in product usage process 16.55 13.47 13 45607 64961 64388151
Erythema 16.54 13.47 72 45548 186998 64266114
Dyspnoea 16.51 13.47 385 45235 718289 63734823
Haemorrhagic disorder 16.48 13.47 11 45609 1388 64451724
Depressed mood 16.47 13.47 65 45555 40947 64412165
Loss of consciousness 16.46 13.47 52 45568 148313 64304799
Angina bullosa haemorrhagica 16.45 13.47 6 45614 200 64452912
Graft versus host disease in lung 16.43 13.47 9 45611 795 64452317
Myositis 16.41 13.47 36 45584 16341 64436771
Angioedema 16.22 13.47 12 45608 61809 64391303
Headache 15.96 13.47 271 45349 529196 63923916
Muscle haemorrhage 15.92 13.47 20 45600 5733 64447379
Nasopharyngitis 15.84 13.47 78 45542 195995 64257117
Papilloma excision 15.83 13.47 3 45617 5 64453107
Stomatitis 15.81 13.47 132 45488 109473 64343639
Therapy partial responder 15.76 13.47 27 45593 10221 64442891
Pallor 15.74 13.47 4 45616 38777 64414335
Diffuse large B-cell lymphoma 15.54 13.47 27 45593 10334 64442778
Soft tissue infection 15.54 13.47 15 45605 3208 64449904
Pseudohyperkalaemia 15.47 13.47 3 45617 6 64453106
Procedural haemorrhage 15.46 13.47 17 45603 4235 64448877
Erysipelas 15.40 13.47 25 45595 9056 64444056
Migraine 15.40 13.47 13 45607 62664 64390448
Central nervous system fungal infection 15.38 13.47 7 45613 415 64452697
Heart rate decreased 15.36 13.47 10 45610 55057 64398055
Alanine aminotransferase increased 15.23 13.47 49 45571 138982 64314130
Hepatitis B reactivation 15.16 13.47 18 45602 4871 64448241
Rhabdomyolysis 15.12 13.47 26 45594 91700 64361412
Pulmonary embolism 15.07 13.47 53 45567 146303 64306809
Blood immunoglobulin M increased 14.92 13.47 7 45613 445 64452667
Bradycardia 14.89 13.47 39 45581 118180 64334932
Therapeutic product effect incomplete 14.74 13.47 32 45588 103450 64349662
Septic shock 14.69 13.47 126 45494 105311 64347801
Mass 14.66 13.47 33 45587 15243 64437869
Cardiac failure congestive 14.66 13.47 149 45471 130431 64322681
Restlessness 14.51 13.47 5 45615 39780 64413332
Scrotal haematocoele 14.37 13.47 3 45617 10 64453102
Hospice care 14.33 13.47 22 45598 7603 64445509
Injection site bruising 14.29 13.47 4 45616 36369 64416743
Encephalitis 14.18 13.47 29 45591 12542 64440570
Lymph node palpable 14.15 13.47 5 45615 152 64452960
Cystoid macular oedema 14.14 13.47 11 45609 1763 64451349
Eye operation 14.10 13.47 11 45609 1769 64451343
Skin mass 14.06 13.47 21 45599 7085 64446027
Prostate cancer 13.95 13.47 38 45582 19757 64433355
Benign prostatic hyperplasia 13.90 13.47 24 45596 9141 64443971
Confusional state 13.88 13.47 118 45502 261026 64192086
Arrhythmia supraventricular 13.82 13.47 11 45609 1822 64451290
C-reactive protein increased 13.81 13.47 29 45591 94880 64358232
Blood pressure systolic increased 13.77 13.47 9 45611 49444 64403668
Haemoglobin abnormal 13.72 13.47 19 45601 5985 64447127
Ill-defined disorder 13.71 13.47 7 45613 44045 64409067
Bacteraemia 13.63 13.47 46 45574 26865 64426247
Post herpetic neuralgia 13.59 13.47 12 45608 2293 64450819
Eosinophilia 13.52 13.47 5 45615 38071 64415041
Pneumonia pseudomonal 13.49 13.47 17 45603 4886 64448226
Immunodeficiency 13.47 13.47 33 45587 16091 64437021

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EL01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Bruton's tyrosine kinase (BTK) inhibitors
FDA MoA N0000175076 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:76617 BTK inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic lymphoid leukemia, disease indication 92814006
Waldenström macroglobulinemia indication 190818004 DOID:0050747
Malignant lymphoma - small lymphocytic indication 302841002
Chronic graft-versus-host disease indication 402356004
Mantle cell lymphoma indication 443487006
Pregnancy, function contraindication 289908002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.7 Basic
pKa2 0.18 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8476284 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8476284 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8476284 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8476284 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8497277 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8497277 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8497277 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8497277 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8497277 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8703780 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8952015 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8952015 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8952015 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8952015 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8952015 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8476284 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8476284 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8476284 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8476284 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8497277 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8497277 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8497277 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8497277 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8497277 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8703780 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8952015 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8952015 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8952015 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8952015 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8952015 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8703780 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8703780 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8703780 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8703780 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8703780 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8703780 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8476284 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8497277 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8703780 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8703780 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF MANTLE CELL LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF MARGINAL ZONE LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8952015 Dec. 28, 2026 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8563563 April 26, 2027 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8563563 April 26, 2027 TREATMENT OF CHRONIC SMALL LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8563563 April 26, 2027 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8563563 April 26, 2027 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8563563 April 26, 2027 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8563563 April 26, 2027 TREATMENT OF CHRONIC SMALL LYMPHOCYTIC LEUKEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8563563 April 26, 2027 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8563563 April 26, 2027 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8563563 April 26, 2027 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10004746 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10004746 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10004746 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10004746 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10016435 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF MARGINAL ZONE LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10653696 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10751342 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10751342 June 3, 2031 TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10751342 June 3, 2031 TREATMENT OF RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10751342 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8754090 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8999999 June 3, 2031 TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 8999999 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 9125889 June 3, 2031 FOR THE TREATMENT OF PATIENTS WITH WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 9801881 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 9801883 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 9814721 June 3, 2031 TREATMENT OF MARGINAL ZONE LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10004746 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10004746 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10004746 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10004746 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10016435 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF MARGINAL ZONE LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10478439 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10653696 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10751342 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10751342 June 3, 2031 TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10751342 June 3, 2031 TREATMENT OF RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10751342 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8754090 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8999999 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8999999 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LEUKEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 8999999 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 9125889 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 9801881 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 9801883 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 9814721 June 3, 2031 TREATMENT OF MARGINAL ZONE LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10016435 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF MARGINAL ZONE LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10653696 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8754090 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9125889 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801881 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801881 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801883 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801883 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9814721 June 3, 2031 TREATMENT OF MARGINAL ZONE LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10016435 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF MARGINAL ZONE LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10653696 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8754090 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9125889 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801881 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801881 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801883 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801883 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9814721 June 3, 2031 TREATMENT OF MARGINAL ZONE LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10016435 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF MARGINAL ZONE LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10653696 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8754090 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9125889 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801881 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801881 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801883 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801883 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9814721 June 3, 2031 TREATMENT OF MARGINAL ZONE LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10004746 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10016435 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF MARGINAL ZONE LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10478439 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10653696 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10751342 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8754090 June 3, 2031 TREATMENT OF MANTLE CELL LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 8999999 June 3, 2031 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9125889 June 3, 2031 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801881 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801881 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801883 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9801883 June 3, 2031 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9814721 June 3, 2031 TREATMENT OF MARGINAL ZONE LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 9540382 Aug. 18, 2033 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 9540382 Aug. 18, 2033 TREATMENT OF MANTLE CELL LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 9540382 Aug. 18, 2033 TREATMENT OF MARGINAL ZONE LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 9540382 Aug. 18, 2033 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 9540382 Aug. 18, 2033 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 9540382 Aug. 18, 2033 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 9540382 Aug. 18, 2033 TREATMENT OF MANTLE CELL LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 9540382 Aug. 18, 2033 TREATMENT OF MARGINAL ZONE LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 9540382 Aug. 18, 2033 TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 9540382 Aug. 18, 2033 TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10463668 Oct. 24, 2034 TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 10695350 Oct. 24, 2034 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE REFRACTORY TO SYSTEMIC THERAPY
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 9795604 Oct. 24, 2034 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 9795604 Oct. 24, 2034 TREATMENT OF ADULT PATIENTS WITH CYCLOSPORIN-RESISTANT, STEROID-DEPENDENT/REFRACTORY, OR STEROID RESISTANT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL 9795604 Oct. 24, 2034 TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10463668 Oct. 24, 2034 TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 10695350 Oct. 24, 2034 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE REFRACTORY TO SYSTEMIC THERAPY
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 9795604 Oct. 24, 2034 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL 9795604 Oct. 24, 2034 TREATMENT OF ADULT PATIENTS WITH CYCLOSPORIN-RESISTANT, STEROID-DEPENDENT/REFRACTORY, OR STEROID RESISTANT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10463668 Oct. 24, 2034 TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10695350 Oct. 24, 2034 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE REFRACTORY TO SYSTEMIC THERAPY
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9795604 Oct. 24, 2034 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9795604 Oct. 24, 2034 TREATMENT OF ADULT PATIENTS WITH CYCLOSPORIN-RESISTANT, STEROID-DEPENDENT/REFRACTORY, OR STEROID RESISTANT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10463668 Oct. 24, 2034 TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10695350 Oct. 24, 2034 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE REFRACTORY TO SYSTEMIC THERAPY
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9795604 Oct. 24, 2034 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9795604 Oct. 24, 2034 TREATMENT OF ADULT PATIENTS WITH CYCLOSPORIN-RESISTANT, STEROID-DEPENDENT/REFRACTORY, OR STEROID RESISTANT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10463668 Oct. 24, 2034 TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10695350 Oct. 24, 2034 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE REFRACTORY TO SYSTEMIC THERAPY
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9795604 Oct. 24, 2034 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9795604 Oct. 24, 2034 TREATMENT OF ADULT PATIENTS WITH CYCLOSPORIN-RESISTANT, STEROID-DEPENDENT/REFRACTORY, OR STEROID RESISTANT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10463668 Oct. 24, 2034 TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 10695350 Oct. 24, 2034 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE REFRACTORY TO SYSTEMIC THERAPY
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9795604 Oct. 24, 2034 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL 9795604 Oct. 24, 2034 TREATMENT OF ADULT PATIENTS WITH CYCLOSPORIN-RESISTANT, STEROID-DEPENDENT/REFRACTORY, OR STEROID RESISTANT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL Jan. 25, 2022 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO INCLUDE EFFICACY AND SAFETY DATA FROM A STUDY IN PATIENTS WITH TREATMENT NAIVE CLL/SLL TREATED WITH IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB OR CHLORAMBUCIL IN COMBINATION WITH OBINUTUZUMAB
70MG IMBRUVICA PHARMACYCLICS INC N205552 Dec. 20, 2017 RX CAPSULE ORAL Jan. 25, 2022 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO INCLUDE EFFICACY AND SAFETY DATA FROM A STUDY IN PATIENTS WITH TREATMENT NAIVE CLL/SLL TREATED WITH IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB OR CHLORAMBUCIL IN COMBINATION WITH OBINUTUZUMAB
140MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL Jan. 25, 2022 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO INCLUDE EFFICACY AND SAFETY DATA FROM A STUDY IN PATIENTS WITH TREATMENT NAIVE CLL/SLL TREATED WITH IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB OR CHLORAMBUCIL IN COMBINATION WITH OBINUTUZUMAB
280MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL Jan. 25, 2022 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO INCLUDE EFFICACY AND SAFETY DATA FROM A STUDY IN PATIENTS WITH TREATMENT NAIVE CLL/SLL TREATED WITH IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB OR CHLORAMBUCIL IN COMBINATION WITH OBINUTUZUMAB
420MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL Jan. 25, 2022 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO INCLUDE EFFICACY AND SAFETY DATA FROM A STUDY IN PATIENTS WITH TREATMENT NAIVE CLL/SLL TREATED WITH IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB OR CHLORAMBUCIL IN COMBINATION WITH OBINUTUZUMAB
560MG IMBRUVICA PHARMACYCLICS INC N210563 Feb. 16, 2018 RX TABLET ORAL Jan. 25, 2022 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO INCLUDE EFFICACY AND SAFETY DATA FROM A STUDY IN PATIENTS WITH TREATMENT NAIVE CLL/SLL TREATED WITH IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB OR CHLORAMBUCIL IN COMBINATION WITH OBINUTUZUMAB
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL Jan. 29, 2022 TREATMENT OF PATIENTS WITH WALDENSTROMS MACROGLOBULINEMIA
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL March 4, 2023 INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE THERAPY)
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL May 6, 2023 FOR TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL)
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL Jan. 18, 2024 TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
140MG IMBRUVICA PHARMACYCLICS INC N205552 Nov. 13, 2013 RX CAPSULE ORAL Aug. 2, 2024 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Tyrosine-protein kinase BTK Kinase INHIBITOR Ki 9.14 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Tyrosine-protein kinase ABL1 Kinase IC50 7.07 CHEMBL
Epidermal growth factor receptor Kinase IC50 8.25 CHEMBL
Breakpoint cluster region protein Kinase Kd 5.84 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 5.80 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase IC50 7.43 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase IC50 5.26 CHEMBL
Tyrosine-protein kinase CSK Kinase IC50 8.66 CHEMBL
Cytoplasmic tyrosine-protein kinase BMX Kinase IC50 9.10 CHEMBL
LIM domain kinase 1 Kinase Kd 4.68 CHEMBL
Tyrosine-protein kinase Fer Kinase IC50 5.09 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 6.04 CHEMBL
Fibroblast growth factor receptor 2 Kinase IC50 6.55 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 6.23 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 7.24 CHEMBL
Protein-tyrosine kinase 6 Kinase IC50 8.48 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 5.77 CHEMBL
Serine/threonine-protein kinase LATS1 Kinase Kd 5.72 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 6.61 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 5.96 CHEMBL
Platelet glycoprotein VI Unclassified IC50 6.92 CHEMBL
Receptor-interacting serine/threonine-protein kinase 3 Kinase Kd 7.07 CHEMBL
Nuclear receptor subfamily 4 group A member 3 Nuclear other IC50 7.11 CHEMBL
Tyrosine-protein kinase Lyn Kinase Ki 7.85 SCIENTIFIC LITERATURE
Tyrosine-protein kinase JAK3 Kinase INHIBITOR IC50 7.50 SCIENTIFIC LITERATURE
Proto-oncogene tyrosine-protein kinase Src Kinase INHIBITOR IC50 7.72 SCIENTIFIC LITERATURE
Tyrosine-protein kinase Lck Kinase INHIBITOR IC50 8.20 SCIENTIFIC LITERATURE
Tyrosine-protein kinase Yes Kinase INHIBITOR IC50 8.39 SCIENTIFIC LITERATURE
Tyrosine-protein kinase Fyn Kinase INHIBITOR IC50 7.54 SCIENTIFIC LITERATURE
Receptor tyrosine-protein kinase erbB-2 Kinase INHIBITOR IC50 8.19 SCIENTIFIC LITERATURE
Tyrosine-protein kinase HCK Kinase INHIBITOR IC50 7.54 SCIENTIFIC LITERATURE
Receptor tyrosine-protein kinase erbB-4 Kinase INHIBITOR IC50 8.47 SCIENTIFIC LITERATURE
Tyrosine-protein kinase Fgr Kinase INHIBITOR IC50 8.48 SCIENTIFIC LITERATURE
Tyrosine-protein kinase ITK/TSK Kinase INHIBITOR IC50 8.31 SCIENTIFIC LITERATURE
Tyrosine-protein kinase Tec Kinase INHIBITOR IC50 8.16 SCIENTIFIC LITERATURE
Tyrosine-protein kinase TXK Kinase INHIBITOR IC50 8.70 SCIENTIFIC LITERATURE
Tyrosine-protein kinase Blk Kinase INHIBITOR IC50 10 SCIENTIFIC LITERATURE
Redox-regulatory protein FAM213A Unclassified IC50 6.05 CHEMBL

External reference:

IDSource
D10223 KEGG_DRUG
4032872 VANDF
CHEBI:76612 CHEBI
1E8 PDB_CHEM_ID
CHEMBL1873475 ChEMBL_ID
C551803 MESH_SUPPLEMENTAL_RECORD_UI
6912 IUPHAR_LIGAND_ID
9566 INN_ID
DB09053 DRUGBANK_ID
1X70OSD4VX UNII
24821094 PUBCHEM_CID
1442981 RXNORM
207254 MMSL
29840 MMSL
d08170 MMSL
015287 NDDF
710228002 SNOMEDCT_US
715598009 SNOMEDCT_US
C3501358 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Imbruvica HUMAN PRESCRIPTION DRUG LABEL 1 57962-007 SUSPENSION 70 mg ORAL NDA 31 sections
Imbruvica HUMAN PRESCRIPTION DRUG LABEL 1 57962-014 TABLET, FILM COATED 140 mg ORAL NDA 31 sections
Imbruvica HUMAN PRESCRIPTION DRUG LABEL 1 57962-014 TABLET, FILM COATED 140 mg ORAL NDA 31 sections
Imbruvica HUMAN PRESCRIPTION DRUG LABEL 1 57962-070 CAPSULE 70 mg ORAL NDA 31 sections
Imbruvica HUMAN PRESCRIPTION DRUG LABEL 1 57962-070 CAPSULE 70 mg ORAL NDA 31 sections
Imbruvica HUMAN PRESCRIPTION DRUG LABEL 1 57962-140 CAPSULE 140 mg ORAL NDA 31 sections
Imbruvica HUMAN PRESCRIPTION DRUG LABEL 1 57962-140 CAPSULE 140 mg ORAL NDA 31 sections
Imbruvica HUMAN PRESCRIPTION DRUG LABEL 1 57962-280 TABLET, FILM COATED 280 mg ORAL NDA 31 sections
Imbruvica HUMAN PRESCRIPTION DRUG LABEL 1 57962-280 TABLET, FILM COATED 280 mg ORAL NDA 31 sections
Imbruvica HUMAN PRESCRIPTION DRUG LABEL 1 57962-420 TABLET, FILM COATED 420 mg ORAL NDA 31 sections
Imbruvica HUMAN PRESCRIPTION DRUG LABEL 1 57962-420 TABLET, FILM COATED 420 mg ORAL NDA 31 sections
Imbruvica HUMAN PRESCRIPTION DRUG LABEL 1 57962-560 TABLET, FILM COATED 560 mg ORAL NDA 31 sections
Imbruvica HUMAN PRESCRIPTION DRUG LABEL 1 57962-560 TABLET, FILM COATED 560 mg ORAL NDA 31 sections